World Health Organization Issues Warning Over Acute Lack of Weight-Loss Medications
Fewer than a tenth of patients that would benefit from obesity jabs like Wegovy are able to get them, caution the World Health Organization as it publishes its initial advice on the drugs.
Considering more than one billion individuals worldwide currently living with obesity, it is advocating for broader and more equitable access to GLP-1 medication.
Based on estimates, more than two billion will be obese by 2030 without intervention.
"The new guidelines acknowledges that obesity is a chronic disease that can be managed with comprehensive and continuous support," stated WHO director-general Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and supply-chain constraints are significant obstacles to broad access to the jabs that can aid individuals in losing significant body mass, says the agency.
GLP-1 Therapy Shortage
Even in the current most optimistic scenario, the supply of such drugs might only reach about 100 million people – under 10% of those who need them, per the health organization.
The advice urges nations and manufacturers to widen availability, by measures such as patent sharing.
Exclusive production rights on a key compound – the primary ingredient of a leading brand – is scheduled to end in multiple countries in 2026.
How Weight-Loss Jabs Operate
GLP-1 drugs imitate a biological compound to slow digestion, reduce hunger and boost feelings of fullness so individuals consume fewer calories.
Individuals usually start to lose weight within a few weeks of starting on the regular doses.
Evidence indicates people may regain a significant portion after a year of halting the treatment, because their normal food cravings come back.
Being above a healthy weight raises your risk for experiencing medical conditions, like type 2 diabetes, heart disease, stroke, and specific malignancies.
Obesity concerns people in all nations and was associated with 3.7 million fatalities worldwide in 2024, as per the WHO.
